N-terminally chemically modified protein compositions and...

Details N-terminally chemically modified protein compositions and... N-terminally chemically modified protein compositions and...

2006-08-15

2006-08-15

Chism, B. Dell (Department: 1654)

Drug, bio-affecting and body treating compositions

Lymphokine

C424S085100, C514S002600, C530S350000

Reexamination Certificate

active

07090835

ABSTRACT:
Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.

REFERENCES:
patent: 1609546 (1926-12-01), Harris
patent: 3772264 (1973-11-01), Bayer et al.
patent: 4002531 (1977-01-01), Royer
patent: 4179337 (1979-12-01), Davis et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4695623 (1987-09-01), Stabinsky
patent: 4766106 (1988-08-01), Katre et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 4810643 (1989-03-01), Souza
patent: 4833127 (1989-05-01), Ono et al.
patent: 4847325 (1989-07-01), Shadle et al.
patent: 4894226 (1990-01-01), Aldwin et al.
patent: 4897471 (1990-01-01), Stabinsky
patent: 4904584 (1990-02-01), Shaw
patent: 5109120 (1992-04-01), Ueno et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5194592 (1993-03-01), Yoshida
patent: 5214132 (1993-05-01), Kuga et al.
patent: 5218092 (1993-06-01), Sasaki et al.
patent: 5252714 (1993-10-01), Harris et al.
patent: 5281698 (1994-01-01), Nitecki
patent: 5324844 (1994-06-01), Zalipsky
patent: 5349052 (1994-09-01), Delgado et al.
patent: 5372808 (1994-12-01), Blatt et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5532341 (1996-07-01), Welte et al.
patent: 5581476 (1996-12-01), Osslund
patent: 5589356 (1996-12-01), Tam
patent: 5597797 (1997-01-01), Clark
patent: 5612460 (1997-03-01), Zalipsky
patent: 5646113 (1997-07-01), Attie et al.
patent: 5661122 (1997-08-01), Clark et al.
patent: 5672662 (1997-09-01), Harris et al.
patent: 5747646 (1998-05-01), Hakimi et al.
patent: 5770577 (1998-06-01), Kinstler et al.
patent: 5795569 (1998-08-01), Bartley et al.
patent: 5824778 (1998-10-01), Ishikawa et al.
patent: 5824784 (1998-10-01), Kinstler et al.
patent: 5935924 (1999-08-01), Bunting et al.
patent: 5985265 (1999-11-01), Kinstler et al.
patent: 6027720 (2000-02-01), Kuga et al.
patent: 6166183 (2000-12-01), Ishikawa et al.
patent: 6673347 (2004-01-01), Offord et al.
patent: A-10948/92 (1992-08-01), None
patent: 29 30 542 (1981-02-01), None
patent: 0 154 316 (1985-09-01), None
patent: 0 098 110 (1986-09-01), None
patent: 210 761 (1987-02-01), None
patent: 215 126 (1987-03-01), None
patent: 229 108 (1987-07-01), None
patent: 236 987 (1987-09-01), None
patent: 0 243 153 (1987-10-01), None
patent: 247 860 (1987-12-01), None
patent: 256 843 (1988-02-01), None
patent: 0 272 703 (1988-06-01), None
patent: 0 335 423 (1989-10-01), None
patent: 0 340 741 (1989-11-01), None
patent: 370 205 (1990-05-01), None
patent: 0 401 384 (1990-12-01), None
patent: 402 378 (1990-12-01), None
patent: 426 488 (1991-05-01), None
patent: 0 442 724 (1991-08-01), None
patent: 0 456 200 (1991-11-01), None
patent: A-76380/91 (1991-11-01), None
patent: 0 459 630 (1991-12-01), None
patent: 0 473 268 (1992-03-01), None
patent: 490 584 (1992-06-01), None
patent: 510 356 (1992-10-01), None
patent: 0 539 167 (1993-04-01), None
patent: 567 566 (1993-11-01), None
patent: 721 958 (1996-07-01), None
patent: 2 193 631 (1988-02-01), None
patent: 57-192435 (1982-11-01), None
patent: 61-42558 (1986-09-01), None
patent: 62-115280 (1987-05-01), None
patent: 62-129298 (1987-06-01), None
patent: 62-236488 (1987-10-01), None
patent: 62-236497 (1987-10-01), None
patent: 62-289522 (1987-12-01), None
patent: 62-503171 (1987-12-01), None
patent: 63-10800 (1988-01-01), None
patent: 63-60938 (1988-03-01), None
patent: 63-500636 (1988-03-01), None
patent: 63-126900 (1988-05-01), None
patent: 1-26677 (1989-05-01), None
patent: WO 87/00056 (1987-01-01), None
patent: WO-87/01132 (1987-02-01), None
patent: WO 89/10932 (1989-12-01), None
patent: WO 89/05824 (1990-02-01), None
patent: WO 90/04606 (1990-05-01), None
patent: WO 90/05534 (1990-05-01), None
patent: WO-90/09798 (1990-09-01), None
patent: WO-90/12874 (1990-11-01), None
patent: WO 91/05798 (1991-05-01), None
patent: WO 92/06707 (1992-04-01), None
patent: WO 92/16221 (1992-10-01), None
patent: WO 93/00109 (1993-01-01), None
patent: WO 94/00913 (1993-12-01), None
patent: WO 94/12219 (1994-06-01), None
patent: WO 95/00846 (1995-01-01), None
patent: WO 95/32003 (1995-11-01), None
patent: WO-96/11953 (1996-04-01), None
Abuchowski et al., inEnzymes as Drugs, J.S. Holcerberg and J. Roberts (Eds.), pp. 367-383 (1981).
Balmer, DICP,The Annals of Pharmcotherapy, 24:761-767 (1990).
Boehringer Mannheim,Biochemica Katalog, pp. 362 (1994).
Chamow et al., “Modification of CD4 immunoadhesin with monomethoxypoly (ethylene glycol) aldehyde via reductive alkylation,”Bioconjugate Chem., 5:133-140 (1994).
Delgado et al., “Coupling of PEG to Protein by Activation with Treysl Chloride, Applications in Immunoaffinity Cell Preparation,” in Fisher et al., Eds.,Separations Using Aqueous Phase Systems, Applications in Cell Biology and Biotechnology, Plenum Press, New York, NY pp. 211-213 (1989).
Francis et al., inStability of Protein Pharmaceuticals: In Vivo Pathways of Degradation and Strategies for Protein Stabilization, Ahern, T. and Manning, M.C. (Eds.), Plenum Press, New York, N.Y. (1991).
Francis, “Protein Modification and Fusion Proteins”,Focus on Growth Factors, 3:4-10 (May 1992).
Gaertner et al., “Site specific attachment of functionalized poly(ethylene glycol) to the amin terminus of proteins,”Bioconjugate Chem., 7(1):38-44 (1996).
Hill et al., “The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors,”Proc. Natl. Acad. Sci., USA, 90(11):5167-5171 (Jun. 1993).
Klein et al., “Isolation and structural characterization of Three Isoforms of Recombinant Consensus Alpha Interferon,”Arc Biochem. Biophys., 276:531-537 (1990).
Klein et al., “Structural Characterization of Recombinant Consensus Interferon-Alpha,”J. Chromatog., 454:205-215 (1988).
McGoff et al., “Analysis of Polyethylene Glycol Modified Superoxide Dismutase by Chromatographic, Electrophoretic, Light Scattering, Chemical and Enzymatic Methods,”Chem. Pharm. Bull., 36(8):3079-3091 (1988).
Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co., Easton, PA 18042, pp. 1435-1712 (1990).
Rose et al., “Preparation of Well-Defined Protein Conjugates Using Enzyme-Assisted Reverse Proteolysis,”Bioconjugate Chemistry, 2(3):154-159 (1991).
Sada et al., “Resistance to Proteolysis of Antibody Ligands Modified With Polyehtylene Glycol,”J. Fermentation and Bioengineering 71(2):137-139 (1991).
Stryer, inBiochemistry, 2nd Edition, Table 4-1, pp. 80 (1981).
Wetzel et al., “A General Method for Highly Selective Cross-Linking of Unprotected Polypeptides Via pH-Controlled Modification of N-Terminal Alpha-AMino Groups,”Bioconjugates Chem., 1(2):114-122 (1990).
Asano, et al., “A Colorimetric Microassay for the Biological Activity of Human Granulocyte Colony-Stimulating Factor Using Murine Myeoblastic Leukemia, NSF-60 Cells,”Japan Pharmacol. Ther., 19:2767-2773 (1991).
Bensinger, et al. “Autologous Transplantation with Peripheral Blood Mononuclear Cells Collected After Administratjon of Recombinant Granulocyte Stimulating Factor,”Blood 81(11):3158-3163 (1993).
Bodine, D., “Mobilization of Peripheral Blood ‘Stem’ Cells: Where there is smoke, is there fire?”,Experimental Hematology, 23:293-295 (1995).
Brugger et al., “Mobilization of Peripheral Blood Progenitor Cells by Sequential Administration of Interleukin-3 and Granulocyte-Macrophage Colony-Stimulating Factor Following Polychemotherapy with Etopside, Ifosamide, and Cisplatin,”Blood 79:1193-1200 (1992).
Delgado, et al. “The Uses and Properties of PEG-Linked Proteins,”Critical Reviews in Therapeutic Drug Carrier Systems, 9:249-304 (1992).
Goodson, et al., “Site-directed Pegylation of Recombinant Interleukin-2 at its Glycos

Affiliated with

Also associated with

Rating

N-terminally chemically modified protein compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with N-terminally chemically modified protein compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-terminally chemically modified protein compositions and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3634457